June 17 (Reuters) - U.S. FDA:
* US FDA approves new indication for novartis' tasigna
* US FDA says approval expands use in treatment of rare type of leukemia
* US FDA says new indication expands the use of tasigna to adult patients in
earlier stages of cml
(New York Equities Desk; tel: +1 646 223 6000) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
* US FDA approves new indication for novartis' tasigna
* US FDA says approval expands use in treatment of rare type of leukemia
* US FDA says new indication expands the use of tasigna to adult patients in
earlier stages of cml
(New York Equities Desk; tel: +1 646 223 6000) COPYRIGHT Copyright Thomson Reuters 2010. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.